Clinical Trials Browser

poly(I).poly(c12,U) × Clear all

NCT04093323 2026-02-25

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2 Terminated

Melanoma

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

24 enrolled 59 charts

Ovarian Cancer Recurrent

NCT04379518 2026-01-13

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Phase 1/2 Terminated

4 enrolled 30 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT05494697 2025-10-14

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Phase 2 Suspended

Gastrointestinal

Pancreatic Neoplasms

NCT03899987 2025-08-27

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Phase 1/2 Terminated

Triple Negative Breast Neoplasms

NCT05927142 2025-02-25

DURIPANC

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT01545141 2023-10-27

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Phase 1/2 Terminated

15 enrolled 9 charts

Gastrointestinal

Neoplasm Metastasis, Recurrence, Colorectal Neoplasms

NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Phase 1 Completed

9 enrolled 17 charts

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03599453 2023-07-18

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Phase EARLY_PHASE1 Completed

Triple Negative Breast Neoplasms

NCT03403634 2022-03-02

Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver

Phase 2 Completed

19 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT04119830 2022-02-08

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT01312389 2021-11-15

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1/2 Terminated

3 enrolled 4 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02151448 2020-07-20

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

Phase 1/2 Completed

64 enrolled 18 charts

Peritoneal Neoplasms

NCT01355393 2020-02-10

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Breast Neoplasms, Male